Molecular Partners expects to begin Phase 1 trials for its DLL3-targeting cancer therapy MP0712 in 2025.

Molecular Partners announced its Q3 2025 financial results and updated clinical progress, stating that the Phase 1 trial for its DLL3-targeting radio-DARPin therapy, MP0712, is expected to begin in 2025. The company reported ongoing development of its pipeline, with MP0712 advancing toward clinical evaluation for treating cancers expressing the DLL3 protein. No further details on trial design or patient enrollment were provided at this time.